Newleos Therapeutics Appoints Timothy Noyes as President & CEO

Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing treatments for neuropsychiatric disorders, has appointed Timothy Noyes as President and Chief Executive Officer.

Noyes succeeds David Donabedian, Ph.D., Founding President and CEO of Newleos and Executive Partner at Longwood Fund, who will continue to serve the company in an advisory capacity.

Experience

Noyes brings to Newleos more than 30 years of experience and a track record of leading biopharmaceutical companies through critical phases of innovation and growth. As CEO, he will play an instrumental role in driving the advancement of Newleos’ pipeline of first-in-class product candidates across multiple high-unmet-need mental illnesses, including generalized anxiety disorder, social anxiety disorder, and substance use disorders.

Noyes most recently served as CEO of Aerovate Therapeutics where, prior to its merger with Jade Biosciences, he guided the company through its successful IPO and advanced its lead clinical program for pulmonary arterial hypertension through a global Phase 2/3 trial.

Noyes also previously served as CEO of Proteon Therapeutics where he built a team that successfully completed an IPO and advanced an innovative biologic for blood vessel remodeling from pre-clinical development through Phase 3 clinical trials.

Earlier in his career, he held several senior leadership roles with GelTex Pharmaceuticals where he led the commercial launch of Renagel for patients with end-stage renal disease. Following the acquisition of GelTex by Genzyme, Noyes served as President of Genzyme’s Renal Division and President of GelTex. Noyes began his career at Merck, serving in commercial roles in the company’s hypertension and heart failure group and managed care division.

Noyes received an A.B. from Harvard College and an M.B.A. from Harvard Business School.

“I am thrilled to join Newleos as President and CEO. The company is at a pivotal inflection point, translating strong science into clinical momentum across programs that could redefine how anxiety and related disorders are treated,” said Noyes. “I look forward to working with this talented team to continue building a leading neuropsychiatric company and advancing our mission of delivering next-generation therapies for patients who have long been underserved.”